Vitamins that may be helpful
L-carnitine is an amino acid needed to transport fats into the mitochondria (the place in the cell where fats are turned into energy). Adequate energy production is essential for normal heart function. Several studies using 1 gram of L-carnitine two to three times per day showed an improvement in heart function and a reduction in symptoms of angina.5 6 7 Coenzyme Q10 also contributes to the energy-making mechanisms of the heart. Angina patients given 150 mg of coenzyme Q10 each day have experienced greater ability to exercise without experiencing chest pain.8 This has been confirmed in independent investigations.9
Low levels of antioxidant vitamins in the blood, particularly vitamin E, are associated with greater rates of angina.10 This is true even when smoking and other risk factors for angina are taken into account. Early short-term studies using 300 IU (International Units) per day of vitamin E could not find a beneficial action on angina.11 A later study supplementing small amounts of vitamin E (50 IU per day) for longer periods of time showed a minor benefit in people suffering angina.12 Those affected by variant angina have been found to have the greatest deficiency of vitamin E compared with other angina patients.13
Nitroglycerin and similar drugs cause dilation of arteries by interacting with nitric oxide, a potent stimulus for dilation. Nitric oxide is made from arginine, a common amino acid. Blood cells in people with angina are known to make insufficient nitric oxide,14 which may in part be due to abnormalities of arginine metabolism. Taking 2 grams of arginine three times per day for as little as three days has improved the ability of angina sufferers to exercise.15 Seven of ten people with severe angina improved dramatically after taking 9 grams of arginine per day for three months in an uncontrolled study.16 Detailed studies have investigated the mechanism of arginine and have proven it operates by stimulating blood vessel dilation.17
NAC (N-acetyl cysteine) may improve the effects of nitroglycerin in people with angina.18 People with unstable angina who took 600 mg of NAC three times daily in combination with a nitroglycerin transdermal (skin) patch for four months had significantly lower rates of subsequent heart attacks than did people who used either therapy alone or placebo.19
Magnesium deficiency may be a contributing factor for spasms that occur in coronary arteries, particularly in variant angina.20 21 While studies have used injected magnesium to stop such attacks effectively,22 23 it is unclear whether oral magnesium would be effective in preventing or treating blood vessel spasms. One double-blind study of patients with exercise-induced angina, however, showed that oral magnesium supplementation (365 mg twice a day) for 6 months significantly reduced the incidence of exercise-induced chest pain, compared with a placebo.24
In a controlled study, men with severe coronary heart disease were given an exercise test, after which they took either 15 grams of ribose or a placebo four times daily for three days. Compared with the initial test, men taking ribose were able to exercise significantly longer before experiencing chest pain and before abnormalities appeared on their electrocardiogram (ECG), but only the ECG changes were significantly improved compared with those in the placebo group.25 Sports supplement manufacturers recommend 1 to 10 grams per day of ribose, while heart disease patients and people with rare enzyme deficiencies have been given up to 60 grams per day.
Bromelain has been reported in a preliminary study to relieve angina. In that study, 600 people with cancer were receiving bromelain (400 to 1,000 mg per day). Fourteen of those individuals had been suffering from angina. In all 14 cases, the angina disappeared within 4 to 90 days after starting bromelain.26 However, as there was no control group in the study, the possibility of a placebo effect cannot be ruled out. Bromelain is known to prevent excessive stickiness of blood platelets,27 which is believed to be one of the triggering factors for angina.
Fish oil, which contains the fatty acids known as EPA and DHA, has been studied in the treatment of angina. In some studies, enough fish oil to provide a total of about 3 grams of EPA and 2 grams of DHA has reduced chest pain as well as the need for nitroglycerin;28 other investigators could not confirm these findings.29 People who take fish oil may also need to take vitamin E to protect the oil from undergoing potentially damaging oxidation in the body.30 It is not known how much vitamin E is needed to prevent such oxidation; the amount required would presumably depend on the amount of fish oil used. In one study, 300 IU of vitamin E per day prevented oxidation damage in individuals taking 6 grams of fish oil per day.31
Are there any side effects or interactions?
Refer to the individual supplement for information about any side effects or interactions.
1. LaCroix AZ, Mead LA, Liang KY, et al. Coffee consumption and the incidence of coronary heart disease. N Engl J Med 1986;315:977–82.
2. Deanfield J, Wright C, Krikler S, et al. Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. N Engl J Med 1984;310:951–4.
3. Glantz SA, Parmley WW. Passive smoking and heart disease. JAMA 1995;273:1047–53 [review].
4. Todd IC, Ballantyne D. Antianginal efficacy of exercise training: A comparison with beta blockade. Br Heart J 1990;64:14–9.
5. Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: A multicenter, double-blind, randomized, placebo-controlled crossover study. Int J Clin Pharmacol Ther Toxicol 1985;23:569–72.
6. Canale C, Terrachini V, Biagini A, et al. Bicycle ergometer and echocardiographic study in healthy subjects and patients with angina pectoris after administration of L-carnitine: Semiautomatic computerized analysis of M-mode tracing. Int J Clin Pharmacol Ther Toxicol 1988;26:221–4.
7. Cacciatore L, Cerio R, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: A controlled study. Drugs Exp Clin Res 1991;17:225–35.
8. Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 1985;56:247.
9. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Investig 1993;71:S116–23 [review].
10. Riemersma RA, Wood DA, Macintyre CC, et al. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet 1991;337:1–5.
11. Rinzler SH, Bakst H, Benjamin ZH, et al. Failure of alpha-tocopherol to influence chest pain in patients with heart disease. Circulation 1950;1:288–90.
12. Rapola RM, Virtamo J, Haukka JK, et al. Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. JAMA 1996;275:693–8.
13. Miwa K, Miyagi Y, Igawa A, et al. Vitamin E deficiency in variant angina. Circulation 1996;94:14–8.
14. Mollace V, Romeo F, Martuscelli E, et al. Low formation of nitric oxide in polymorphonuclear cells in unstable angina pectoris. Am J Cardiol 1994;74:65–8.
15. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997;80:331–3.
16. Blum A, Porat R, Rosenschein U, et al. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris. Am J Cardiol 1999;83:1488–90.
17. Egashira K, Hirooka Y, Kuga T, et al. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996;94:130–4.
18. Marchetti G, Lodola E, Licciardello L, Colombo A. Use of N-acetylcysteine in the management of coronary artery diseases. Cardiologia 1999;44:633–7.
19. Ardissino D, Merlini PA, Savonitto S, et al. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. J Am Coll Cardiol 1997;29:941–7.
20. Turlapaty P, Altura B. Magnesium deficiency produces spasms of coronary arteries: Relationship to etiology of sudden death ischemic heart disease. Science 1980;208:199–200.
21. Goto K, Yasue H, Okumura K, et al. Magnesium deficiency detected by intravenous loading test in variant angina pectoris. Am J Cardiol 1990;65:709–12.
22. Cohen L, Kitzes R. Magnesium sulfate in the treatment of variant angina. Magnesium 1984;3:46–9.
23. Cohen L, Kitzes R. Prompt termination and/or prevention of cold-pressor-stimulus-induced vasoconstriction of different vascular beds by magnesium sulfate in patients with Prinzmetal’s angina. Magnesium 1986;5:144–9.
24. Shechter M, Bairey Merz CN, et al. Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol 2003;91:517–21.
25. Pliml W, von Arnim T, Stablein A, et al. Effects of ribose on exercise-induced ischemia in stable coronary artery disease. Lancet 1992;340:507–10.
26. Nieper H. Effect of bromelain on coronary heart diseases and angina pectoris. J Int Acad Prev Med 1976;3(2):62–3.
27. Heinicke R, van der Wal L, Yokoyama M. Effect of bromelain (Ananase) on human platelet aggregation. Experientia 1972;28:844–5.
28. Saynor R, Verel D, Gillott T. The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina. Atherosclerosis 1984;50:3–10.
29. Mehta JL, Lopez LM, Lawson D, et al. Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease. Effects on indices of platelet and neutrophil function and exercise performance. Am J Med 1988;84:45–52.
30. Wander RC, Du SH, Ketchum SO, Rowe KE. Alpha-tocopherol influences in vivo indices of lipid peroxidation in postmenopausal women given fish oil. J Nutr 1996;126:643–52.
31. Oostenbrug GS, Mensink RP, Hornstra G. A moderate in vivo vitamin E supplement counteracts the fish-oil-induced increase in in vitro oxidation of human low-density lipoproteins. Am J Clin Nutr 1993;57:827S.
32. Hanack T, Bruckel MH. The treatment of mild stable forms of angina pectoris using Crataegutt® novo. Therapiewoche 1983;33:4331–3 [in German].
33. Conn JJ, Kisane RW, Koons RA, Clark TE. Treatment of angina pectoris with khellin. Ann Intern Med 1952;36:1173–8.
34. Osher HL, Katz KH, Wagner DJ. Khellin in the treatment of angina pectoris. New Engl J Med 1951;244:315–21.
35. Ballegaard S, Pedersen F, Pietersen A, et al. Effects of acupuncture in moderate, stable angina pectoris: a controlled study. J Intern Med 1990;227:25–30.
36. Ballegaard S, Karpatschoff B, Holck JA, et al. Acupuncture in angina pectoris: do psychosocial and neurophysiological factors relate to the effect? Acupunct Electrother Res 1995;20:101–16.
37. Ballegaard S, Norrelund S, Smith DF. Cost-benefit of combined use of acupuncture, Shiatsu and lifestyle adjustment for treatment of patients with severe angina pectoris. Acupunct Electrother Res 1996;21:187–97.
38. Ballegaard S, Jensen G, Pedersen F, Nissen VH. Acupuncture in severe, stable angina pectoris: a randomized trial. Acta Med Scand 1986;220:307–13.
39. Richter A, Herlitz J, Hjalmarson A. Effect of acupuncture in patients with angina pectoris. Eur Heart J 1991;12:175–8.
40. Cunningham D, Brown S, Kaski JC. Effects of transcendental meditation on symptoms and electrocardiographic changes in patients with Cardiac Syndrome X. Am J of Cardiology 2000;85:653–5.
41. Burchett GC. Somatic manifestations of ischemic heart disease. Osteopathic Annals 1976;4:373–5.
42. Nicholas AS, DeBias, et al. A somatic component to myocardial infarction. Br Med J 1985;291:13–7.
43. Beal MC, Kleiber GE. Somatic dysfunction as a predictor of coronary artery disease. J Am Osteopath Assoc 1985; 85:70–5.
44. Beal MC Palpatory testing for somatic dysfunction in patients with cardiovascular disease. J Am Osteopath Assoc 1983;82:73–82.
45. Cox JM, Gorbis S, Dick LM, et al. Palpable musculoskeletal findings in coronary artery disease: results of a double blind study. J Am Osteopath Assoc 1983;82(11)832–6.
46. McGuiness J, Vicenzino B, Wright A. The influence of a cervical mobilization technique on respiratory and cardiovascular function. Man Ther 1997;2:216–20.
47. Vicenzino B, Cartwright T, Collins D. Cardiovascular and respiratory changes produced by lateral glide mobilization of the cervical spine. Man Ther 1998 3(2):67–71.
48. Nansel D, Jansen R, Cremata E, et al. Effects of cervical adjustments on lateral-flexion passive end-range asymmetry and on blood pressure, heart rate and plasma catecholamine levels. J Manip Physiol Ther 1991;14:450–6.